What Amneal Pharmaceuticals, Inc. told the SEC could break it.

Certain of Amneal's products are made by a contract manufacturer located in Taiwan. It explicitly warns that an escalation of China–Taiwan tensions could impair or prevent altogether its ability to source those products. A specific, bridgeable Taiwan-chokepoint dependence within an otherwise US/India-centric manufacturing footprint — distinct from the broader India concentration because the failure mode (geopolitical loss of a single foreign contract manufacturer) is a hard cut-off rather than a cost shock.

“certain of our products utilize a contract manufacturing company in Taiwan, and an escalation of tensions between China and Taiwan could impair or prevent altogether our ability to source these products.”

Amneal produces the majority of its manufactured products at its own facilities in New York, New Jersey and India, plus certain third-party suppliers. India is a core node: 24% of Affordable Medicines product net revenue is manufactured in India, over 6,000 of its 8,500+ employees are located outside the U.S. (primarily India and Ireland), and it has significantly expanded Indian operations. It flags that the heightened India–Pakistan military conflict in May 2025 created regional instability that could disrupt suppliers and logistics partners in South Asia. A real, quantified geographic-concentration exposure to India for both manufacturing and API.

As a generic and specialty drug manufacturer, Amneal is directly exposed to the Inflation Reduction Act's Medicare drug-price negotiation program: it permits CMS to negotiate maximum fair prices on up to 60 drugs by 2029, beginning with 10 drugs in 2026 (small-molecule drugs approved ≥7 years, biologics ≥11 years). Negotiated maximum fair prices on Medicare-covered drugs compress manufacturer pricing power and could reduce revenue on affected products. A specific, named federal-policy exposure central to pharmaceutical economics.

“to negotiate maximum fair prices on up to 60 drugs by 2029, starting with 10 drugs in 2026.”

Amneal flags pharmaceutical trade-policy risk: while there are currently no reciprocal tariffs on pharmaceutical products imported into the U.S., it states this can change at any moment, and Section 232 investigations touching pharmaceutical inputs remain ongoing (FDF and API were exempt from the February 2026 Section 122 10% global tariff as of the filing date). Amneal stresses it has limited reliance on imports from Europe/China and none from Mexico/Canada — most net sales rely on U.S.- or India-produced FDF/API — so the tariff channel is real but partly mitigated. A low-severity but specific, named trade-policy exposure relevant to the supply-shock tariff channel.

Amneal discloses a structural sole-source dependence on its active-pharmaceutical-ingredient (API) and raw-material suppliers. In some cases the raw materials are available from only a single supplier, and even where more than one supplier exists, Amneal has chosen — for its API suppliers for a MAJORITY of its products — to list only one supplier in the product applications it submits to the FDA. Qualifying a new sole-source supplier generally takes 24 to 30 months, and less than one year's termination notice from such a supplier could disrupt its ability to produce the affected drug. Because regulatory requalification is slow, a single API supplier failure cascades directly into product shortages. A genuine, specific sole-source supply risk.

“Further, even if more than one supplier exists, we may choose, and have done so in the case of our API suppliers for a majority of our products, to list only one supplier in our product applications submitted to the FDA.”